Status:
COMPLETED
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
Lead Sponsor:
BioWest Therapeutics Inc
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infe...
Eligibility Criteria
Inclusion
- 18-65 years of age, inclusive
- primary diagnosis of chronic HCV infection
- non-responders to previous pegylated interferon-based therapy
Exclusion
- patients naive to interferon-based therapy for chronic HCV infection
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00217139
Start Date
September 1 2005
End Date
September 1 2006
Last Update
September 29 2006
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Calgary, Alberta, Canada
2
Edmonton, Alberta, Canada
3
Vancouver, British Columbia, Canada
4
Winnipeg, Manitoba, Canada